TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission. The launch is being conducted by Meda AB, (OMX Nordic Exchange: MEDA-A-ST) as part of an exclusive commercialization agreement for Ceplene signed by the two companies in January 2010. Meda is a leading international specialty pharmaceutical company with products sold in 120 countries worldwide and a marketing organization of about 1,200 people throughout Europe.
